Norma O’Donovan

5.6k citations

116 papers · 4.3k indexed · h-index 36

Oncology top 1%
- HER2/EGFR in Cancer Research 67
- Peptidase Inhibition and Analysis 18
- Cancer Treatment and Pharmacology 17
- Cancer-related Molecular Pathways 11
Cancer Research top 2%
Immunology and Allergy top 2%
Molecular Biology top 5%
Radiology, Nuclear Medicine and Imaging top 2%
- Monoclonal and Polyclonal Antibodies Research 25
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 19
- Advanced Breast Cancer Therapies 9
Genetics
- Chronic Lymphocytic Leukemia Research 11

Co-authors: Michael J. Duffy John Crown Martin Clynes Bríd M. Ryan Patricia M. McGowan B. Corkery William M. Gallagher Brigid C. Browne
Cited by: Oncology Cancer Research Immunology and Allergy
Journals: Journal of Clinical Oncology (27 papers)Annals of Oncology (9 papers)Cancer Research (7 papers)
Partner nations: Ireland United States United Kingdom

In The Last Decade

Norma O’Donovan

112 papers receiving 4.2k citations

Peers

Countries citing papers authored by Norma O’Donovan

Since Specialization

Citations

This map shows the geographic impact of Norma O’Donovan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norma O’Donovan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norma O’Donovan more than expected).

Fields of papers citing papers by Norma O’Donovan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norma O’Donovan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norma O’Donovan. The network helps show where Norma O’Donovan may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Norma O’Donovan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Norma O’Donovan Line = papers co-authored together Norma O’Donovan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer PLoS ONE ·Sandra Roche,Patricia Gaule,Nabil S. Shwtar,Nupur Mukherjee,Jordan N. Bentley,Neil T. Conlon,Justine Meiller,Denis M. Collins,Alexandra Canonici,A. A. Galakhova,Alejandra Estepa‐Fernández,Stephen F. Madden,John Crown,Norma O’Donovan,Alex J. Eustace	2023	6
2	Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells Cancers ·Patricia Gaule,Nupur Mukherjee,B. Corkery,Alex J. Eustace,Kathy Gately,Sandra Roche,Robert O’Connor,Kenneth J. O’Byrne,Naomi Walsh,Michael J. Duffy,John Crown,Norma O’Donovan	2019	19
3	The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells Investigational New Drugs ·Alexandra Canonici,S.-L. Chiu,Neil T. Conlon,Denis M. Collins,Neil A. O’Brien,Naomi Walsh,Alex J. Eustace,Norma O’Donovan,John Crown	2018	19
4	Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells International Journal of Oncology ·Martina S.J. McDermott,Alexandra Canonici,В С Заика,Brigid C. Browne,Stephen F. Madden,Neil A. O’Brien,John Crown,Norma O’Donovan	2017	24
5	Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007 Cancer Letters ·Naoise C. Synnott,Matthias R. Bauer,Stephen F. Madden,Courbil Lj,Rut Klinger,Norma O’Donovan,Darran P. O’Connor,William M. Gallagher,John Crown,Alan R. Fersht,Michael J. Duffy	2017	58
6	Alterations to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (T-ADCC) in a lapatinib-resistant HER2+ breast cancer cell line model Annals of Oncology ·莫维光,M Guibourdenche,Brigid C. Browne,Lorraine O’Driscoll,Neil A. O’Brien,Norma O’Donovan,John Crown,Denis M. Collins	2017	1
7	Biomarkers for afatinib and dasatinib treatment in triple negative breast cancer Annals of Oncology ·Alexandra Canonici,Kayla S. Kroneberg,W Westensko,Mattia Cremona,М. П. Ямова,Bryan T. Hennessy,Flavio Solca,John Crown,Norma O’Donovan	2016	4
8	Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells British Journal of Cancer ·Francesco Caiazza,Patricia M. McGowan,Maeve Mullooly,Alan Murray,Naoise C. Synnott,Norma O’Donovan,Dudek Sylwia,Christopher J. Tape,Gillian Murphy,John Crown,Michael J. Duffy	2015	47
9	Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines Cancer Biology & Therapy ·充佳岸原,Patricia M. McGowan,Maura B. Cotter,Maeve Mullooly,Norma O’Donovan,Sweta Rani,Lorraine O’Driscoll,John Crown,Michael J. Duffy	2013	30
10	ADAM-17: a novel therapeutic target for triple negative breast cancer Annals of Oncology ·Patricia M. McGowan,Maeve Mullooly,Francesco Caiazza,高太忠,Stephen F. Madden,Aoife Maguire,John P. Pierce,E. McDermott,John Crown,Norma O’Donovan,Michael J. Duffy	2012	46
11	Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells Investigational New Drugs ·Norma O’Donovan,Annette T. Byrne,Aisling O’Connor,Sharon F. McGee,William M. Gallagher,John Crown	2010	37
12	Synthesis, characterisation and biological evaluation of N-(ferrocenyl)naphthoyl amino acid esters as anticancer agents Dalton Transactions ·Shazzat Rahat Hossain,P Weisan,R H MacMillan,伸夫平田,DERMOT A. O'SULLIVAN,Norma O’Donovan,John Crown,Sunil Varughese,Sylvia M. Draper,K. Dilip,Peter T.M. Kenny	2010	40
13	HER-2 Signaling and Inhibition in Breast Cancer Current Cancer Drug Targets ·Brigid C. Browne,Neil A. O’Brien,Michael J. Duffy,John Crown,Norma O’Donovan	2009	92
14	Alterations in integrin expression modulates invasion of pancreatic cancer cells Journal of Experimental & Clinical Cancer Research ·Naomi Walsh,Martin Clynes,John Crown,Norma O’Donovan	2009	23
15	The role of ADAMs in disease pathophysiology Clinica Chimica Acta ·Michael J. Duffy,Eadaoin McKiernan,Norma O’Donovan,Patricia M. McGowan	2009	56
16	Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells Journal of Proteomics ·Naomi Walsh,Paul Dowling,Norma O’Donovan,Michael Henry,Paula Meleady,Martin Clynes	2008	14
17	Use of a Panel of Novel Genes for Differentiating Breast Cancer from Non-Breast Tissues Tumor Biology ·P.H.E.O. van Mil,Norma O’Donovan,Deirdre Foley,Arnold Hill,Enda McDermott,N. J. O’Higgins,Michael J. Duffy	2007	8
18	Survivin: A promising tumor biomarker Cancer Letters ·Michael J. Duffy,Norma O’Donovan,Donal J. Brennan,William M. Gallagher,Bríd M. Ryan	2007	214
19	Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays. Molecular Cancer ·Lorraine O’Driscoll,Jason McMorrow,Padraig Doolan,Eadaoin McKiernan,Jai Prakash Mehta,Shea Sickles,Patrick Gammell,Helena Joyce,Norma O’Donovan,N. Walsh,Martin Clynes	2006	52
20	Growth hormone regulates growth hormone receptor gene transcription in primary human thyroid cells Molecular and Cellular Endocrinology ·Primus E. Mullis,Norma O’Donovan,Andrée Eblé,Ulrich Marti,Peter Diem,Ulrich Bürgi,Jorge Héctor Razul	2000	5

About Norma O’Donovan

Norma O’Donovan is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 116 papers that have together received 4.3k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (67 papers), Monoclonal and Polyclonal Antibodies Research (25 papers), Lung Cancer Treatments and Mutations (19 papers), Peptidase Inhibition and Analysis (18 papers), Cancer Treatment and Pharmacology (17 papers), Chronic Lymphocytic Leukemia Research (11 papers), Cancer-related Molecular Pathways (11 papers) and Advanced Breast Cancer Therapies (9 papers). The work is most often cited by research in Oncology (2.3k citations), Cancer Research (838 citations) and Immunology and Allergy (266 citations). Norma O’Donovan has collaborated with scholars based in Ireland, United States and United Kingdom. Frequent co-authors include Michael J. Duffy, John Crown, Martin Clynes, Bríd M. Ryan, Patricia M. McGowan, B. Corkery, William M. Gallagher, Brigid C. Browne, Neil A. O’Brien and Eadaoin McKiernan. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Journal of Organometallic Chemistry and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact